Can MRI scans reveal the hidden pattern of muscle damage in a rare muscular dystrophy?
NCT ID NCT05102799
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This study aims to describe the pattern of muscle involvement in people with limb girdle muscular dystrophy caused by mutations in the anoctamin 5 gene. Researchers will collect and analyze MRI scans from 200 participants to see which muscles are affected and how much fat replaces muscle tissue. The goal is to better understand the disease and potentially improve future clinical trial design.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to track disease progression and design future clinical trials for this type of muscular dystrophy.
- What could go wrong
- This is an observational study, so it won't test a treatment. The findings may not directly change patient care, and the MRI patterns may vary widely among individuals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMB GIRDLE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanna Scharff Poulsen
Copenhagen, 2100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI scans reveal how ANO5 muscle disease progresses?
- Virtual group therapy aims to boost social skills in kids with rare muscle disease
- Paving the way: new study aims to sharpen tools for LGMD R1 trials
- One-Time gene therapy aims to halt rare muscle disease
- Experimental gene therapy targets rare muscle disease in first human test
- New study maps key tests for LGMD to speed up drug development